Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.

ABSTRACT:

Background

There is an urgent need to understand the real-world effectiveness of remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods

This was a retrospective comparative effectiveness study. Individuals hospitalized in a large private healthcare network in the United States from 23 February 2020 through 11 February 2021 with a positive test for SARS-CoV-2 and ICD-10 diagnosis codes consistent with symptomatic coronavirus disease 2019 (COVID-19) were included. Remdesivir recipients were matched to controls using time-dependent propensity scores. The primary outcome was time to improvement with a secondary outcome of time to death.

Results

Of 96 859 COVID-19 patients, 42 473 (43.9%) received at least 1 remdesivir dose. Th

SUBMITTER: Garibaldi BT 

PROVIDER: S-EPMC8754724 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature